ReviewEuropean cardiology2023
Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology.
Review in European cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Coronary Plaque Vulnerability and Pericoronary Adipose Tissue Inflammation: Emerging Insights from Advanced CT Imaging.Medicina (Kaunas, Lithuania) · 2026Review
- Cardiovascular Disease and COVID-19: Is There a Place for Mid-Regional Pro-Adrenomedullin? Preliminary Data from a Clinical Cohort.International journal of molecular sciences · 2025Article
- Prevalence and Cardiopulmonary Characteristics of Post-COVID Syndrome at a Hungarian Tertiary Referral Hospital.Journal of clinical medicine · 2025Article
- Has COVID-19 led to more sudden cardiac deaths in football?Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Subclinical patterns of cardiac involvement by transthoracic echocardiography in individuals with mild initial COVID-19.Scientific reports · 2025Article
- Effects of an app-based physical training for long- and post-COVID treatment (A PILOT) study: protocol for a multicentre randomised controlled trial.BMJ open sport & exercise medicine · 2025Article
- Impaired myocardial perfusion and myocardial inflammation of acute myopericarditis associated with COVID-19.Journal of cardiology cases · 2025Article
- Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.Annals of internal medicine · 2024Observational
- Persistence of coronavirus in the cardiac tissue in patients following recovery from COVID-19.Cardiovascular diagnosis and therapy · 2024Article
- Trends in Coronary Artery Anomalies Detection by Coronary Computed Tomography Angiography (CCTA): A Real-Life Comparative Study before and during the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Article
- Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response.Nanotheranostics · 2024Review
- Trajectories of functional and structural myocardial parameters in post-COVID-19 syndrome-insights from mid-term follow-up by cardiovascular magnetic resonance.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lingering cardiac symptoms are increasingly recognised complications of severe acute respiratory syndrome coronavirus 2 infection, now referred to as post-acute cardiovascular sequelae of COVID-19 (PASC). In the acute phase, cardiac injury is driven by cytokine release and stems from ischaemic and thrombotic complications, resulting in myocardial necrosis. Patients with pre-existing cardiac conditions are particularly vulnerable. Myocarditis due to a direct viral infection is rare. Chronic symptoms relate to either worsening of pre-existing heart disease (PASC - cardiovascular disease) or delayed chronic inflammatory condition due to heterogenous immune dysregulation (PASC - cardiovascular syndrome), the latter affecting a broad segment of previously well people. Both PASC presentations are associated with increased cardiovascular risk, long-term disability and reduced quality of life. The recognition and management of PASC in clinical settings remains a considerable challenge. Sensitive diagnostic methods are needed to detect subtler inflammatory changes that underlie the persistent symptoms in PASC - cardiovascular syndrome, alongside considerable clinical experience in inflammatory cardiac conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.